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Bioconjugatesa b s t r a c t
The unnatural amino acids (UAAs) are members of a class of molecules with relevant impacts in the life
sciences. Due to the role of these molecules in the modulation of the chemical and physical properties of
biological and inorganic materials, UAAs have attracted increasing interest in recent years. The aim of this
review is to highlight (i) the most recent and innovative synthetic routes for the preparation of UAAs,
(ii) the recently marketed UAA-based drugs, and (iii) the most promising technological applications
involving novel UAA-containing molecular entities.
 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/3.0/).Proteinogenic amino acids are considered pivotal chiral pool
material. In addition to the 20 well-known amino acids, a plethora
of analogues with modiﬁed side chains and backbones or atypical
stereochemistry can also be considered, widening the scope of
investigation and increasing the chances for success. Although
some of these non-standard amino acids, such as ornithine, which
is present in the urea cycle, are naturally occurring, these amino
acids are generally termed ‘non-natural’ or ‘unnatural’ amino acids
(UAAs). Unlike the proteinogenic amino acids, for which the pre-
ferred collection method is extraction from natural sources, most
non-standard amino acid analogues must be synthesized. For this
reason, as well as the growing awareness of the relevance of these
molecules in several technological contexts, UAAs have been the
subject of a relatively large number of scientiﬁc investigations in
recent decades (Fig. 1). In addition to the use of amino acid scaf-decades
Scholar,folds as building blocks during drug discovery1 and the unusual
role of amino acids as reactants for important drug-like
compounds2 (e.g., benzodiazepines), the conserved backbones
and their variable side chains are potentially relevant for a wide
number of applications, which span from probing protein function
to adhesive agents and biomedical products. Among the increasing
number of publications on this subject, very few general reviews
5350 A. Stevenazzi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5349–5356addressing UAAs, including their synthesis and their use in diverse
ﬁelds, are currently available in the literature. The current review
will focus on a-UAAs, providing an overview of the most recent
and the most innovative synthetic routes for the preparation of
these molecules and an overview of recently marketed UAA-based
drugs. This review will also include a discussion of the most prom-
ising technological applications that involve novel UAA-containing
molecular entities in the life science disciplines and beyond.
Synthesis of UAAs: Access to UAAs has attracted attention in
recent years.3 The synthetic routes that are currently available
can be reduced to a small number of diversity-oriented transfor-
mation categories, which differ from one another with respect to
the starting materials employed and the number of bonds formed
(see Fig. 2). The most intuitive procedures are based on alkylations
that involve glycine equivalents or the widest range of modiﬁca-
tions to amino acid side chains. Multicomponent or tandem reac-
tions that proceed via imines or other activated intermediates
are likely the most synthetically attractive routes, even though
these reactions often lack efﬁciency or stereoselectivity. Due to
the large number of methodologies and examples available, we
chose to focus our discussion on only the most innovative
approaches, including (but not limited to) the stereoselective
multicomponent synthesis of non-proteinogenic a-amino acids.
Several multicomponent access routes to UAAs involving an
imine as the key intermediate (see Fig. 2a) were discussed in the lit-
erature. The asymmetric Petasis borono–Mannich reaction repre-
sents one of the most powerful and straightforward approaches
for the stereoselective preparation of a-amino acids. Strategies
involving chiral amines, chiral boronate esters, and chiral organo-
catalysts have been employed, but to date, none of these strategies
has yielded satisfactory results in the synthesis of a-amino acids. Li
and Xu4 developed an extremely mild and practical approach for
the asymmetric synthesis of b,c-unsaturated a-amino acids thatFigure 2. Retrosynthetic approaches to a-amino acids: (a) multicomponent reaction
modiﬁcations.employs a highly diastereoselective Lewis acid-promoted Petasis
three-component-reaction of N-tert-butanesulﬁnamide in the pres-
ence of glyoxylic acid and a vinylboronic acid. This reaction was
conducted at room temperature and optimized with respect to
Lewis acid (InBr3), solvent (CH2Cl2), concentration (0.3 M) and time
(12 h), with the aim of enhancing diastereoselectivity and yield
(Fig. 3a). This method has proven efﬁcient and general with respect
to substrate scope and stereocontrol. Not only styryl boronic acids
but also alkenyl and benzo-condensed aryl boronic acids performed
well under the optimized conditions. After establishing carboxyla-
tion reactions of mono-protected N-Boc-a-amido stannanes using
CO2 as a C1 source, Mita and Sato5 developed a one-pot synthesis
of a-amino acids based on imine formation, stannylation or silyla-
tion, and ﬁnal carboxylation (Fig. 3b). This reaction was made pos-
sible by the combination of CsF and Me3Si–SnBu3 or PhMe2Si–Bpin
reagents and gave products with yields up to 91%. a,a-Dialkylgly-
cines are sterically constrained amino acids that are of great inter-
est due to their properties when incorporated into peptides. In fact,
these amino acids increase proteolytic stability and confer speciﬁc
conformations. The synthesis of several a,a-dialkylglycines was
achieved using a solid phase Ugi reaction performed over isocya-
nide functionalized resins, with phenyl acetic acid as the acid
component, 4-methoxybenzylamine as the amine component and
diverse ketones to afford the desired N-acylateda,a-dialkylglycines
in good overall yields (60–80%) after acidolytic cleavage from the
resin (Fig. 3c).6 A recent diversity-oriented approach envisaged a
solvent/catalyst-free Biginelli condensation to prepare a series of
propargylated dihydropyrimidinone scaffolds, which may be con-
sidered cyclic b-amino acids.7 These precursors were further deco-
rated through cycloaddition reactions with small peptide-like
azides synthesized from Ugi or Mannich reactions (Fig. 3d). Various
hydroxyaldehydes were functionalized via base-catalyzed conden-
sation with propargyl bromide before performing the Biginellis via imine; (b) other tandem reactions; (c) glycine equivalents; (d) side chain
Figure 4. Alternative multicomponent/tandem/domino approaches to a-amino acids: (a) multicomponent one-pot approach to a-aryl serine derivatives; (b) synthesis of
N-protected a-amino acid esters; (c) synthesis of a and b homophenylalanine precursors via sequential allylic C–H amination/vinylic C–H arylation; (d) access to bicyclic
b-prolines and a,b,c-triamino acids via a combination of anionic aza-Michael additions, a diazo transfer and 1,3-dipolar cycloadditions.
Figure 3. Multicomponent access to a-amino acids through an imine intermediate: (a) an asymmetric Petasis borono-Mannich access to UAA; (b) Mita and Sato one pot
approach to a-amino acids, based on imine formation, stannylation or silylation, and ﬁnal carboxylation; (c) synthesis of N-acylated a,a-dialkylglycines via solid phase Ugi
reaction.
A. Stevenazzi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5349–5356 5351
5352 A. Stevenazzi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5349–5356reaction in the presence of methyl acetoacetate or ethyl cyanoace-
tate as the CH acidic oxo components and urea as the diamide
component.
Othermulticomponent routes envisage the formation of alterna-
tive activated species as an intermediate. Wang et al. proposed a
multicomponent one-pot approach to a-aryl serine derivatives.8
The reaction involves the in situ Rh-catalyzed generation of ammo-
nium ylides from aryl-substituted diazoacetates and anilines and
the trapping of these molecules by formaldehyde (Fig. 4a). How-
ever, yields were only moderate (30–69%), the substrate scope
was limited to 2-substituted anilines and aryldiazoacetates, and
an asymmetric version of the reaction remains to be investigated.
The synthesis of a series of N-protected non-proteinogenic a-amino
acid esters from glyoxylates and carbamates was reported by Ali
and Fathalla.9 The key hemiacetal intermediates were activated to
a-substitution as trichloroacetimidates or acetates, giving the
desired products in good yields with short reaction times (Fig. 4b).
Also fascinating cascade approaches led to the core formation of
novel UAAs (see Fig. 2b). White et al. exploited Pd(II)/sulfoxide
catalysis to promote a sequential allylic C–H amination/vinylic
C–H arylation, which started from inexpensive commercially
available a-oleﬁns and boronic acids, to provide a wide range of
a- and b-homophenylalanine precursors (Fig. 4c).10 Apart from
the outstanding regio- and E:Z selectivities of this ﬁrst tandem reac-
tion step, the route to the desired enantiomerically pure amino
acids required several steps, with low overall yields. An unprece-
dented combination of anionic aza-Michael additions, a diazo
transfer and 1,3-dipolar cycloadditions was reported by Jahn et al.
to approach bicyclic b-prolines and a,b,c-triamino acids.11 Several
b-substituted Michael acceptors, such as esters or amides, could
be employed, and nonaﬂyl azide was identiﬁed as the reagent of
choice for the diazo transfer (Fig. 4d). Lithium amides were gener-
ated in situ via deprotonation of the corresponding amine with
n-BuLi. The use of chiral amines provided highly diastereoselective
products. a,b,c-Triamino acids were obtained via hydrogenolytic
opening of the pyrazoline ring.
Access to UAAs using glycine derivatives as starting reagents
(see Fig. 2c) or by modifying other amino acids side chains (see
Fig. 2d) has been extensively reviewed in recent years.12–15
However, noteworthy examples continue to be reported in the
literature. An efﬁcient, enantioselective preparation of ﬂuorinated
a-amino acids via Ni-catalyzed Mitsunobu–Tsunoda alkylation of
a chiral nucleophilic glycine equivalent (Fig. 5) with alcoholFigure 5. Ni-catalyzed asymmetric synthesis of ﬂuorinated a-amino acids from
glycine.substrates was recently discussed by Brimble et al.16 Several
diversity-oriented strategies that started from glycine equivalents
were described by Kotha et al.17 Highly atom-economic processes,
such as the Diels–Alder reaction, [2+2+2] cycloaddition, Suzuki–
Miyaura cross-coupling, and oleﬁn metathesis, were employed to
access UAA derivatives and peptides.
Side chain modiﬁcations may be considered the most obvious
transformations for accessing UAAs; nonetheless, some examples
are worth mentioning. The Catellani reaction is one of these trans-
formations. Göbel and Lautens reported the synthesis of simple to
more complex substituted aromatic systems in a Pd-catalyzed cas-
cade fashion; these products were used as the precursors for novel
amino acids with a basic side chain (Fig. 6a).18 Sinha et al. reported
the stereoselective synthesis of 2- and 3-indolylglycine derivatives
and their oxygen analogues starting from 2-iodoheteroarenes.19 A
tandem Sonogashira/cyclization reaction with ethynyloxazolidi-
none gave access to 2-indoylglycine analogues, while 3-indolylgly-
cine derivatives were synthesized from silylated internal alkyne
using Larock’s heteroannulation as the key reaction (Fig. 6b).
UAA-based Drugs Available on the Market: In recent years, the
design of peptidomimetics and peptide analogues has attracted
increasing interest in the ﬁeld of drug research. The discovery of
a multitude of naturally occurring bioactive peptides represented
a source of enlightment for medicinal chemists in the development
of new therapeutic drugs. Although natural amino acid-based pep-
tides ﬁnd wide applications as drugs,20 major drawbacks, such as
rapid proteolytic metabolism and poorly selective interactions,
limit the application of these peptides. Hence, peptidomimetics
could serve as privileged surrogates, maintaining the ability to
modulate and control biological functions while offering several
advantages, such as improved in vivo stability, enhanced potency,
better oral absorption, improved tissue distribution and increased
selectivity during biological responses.21,22 Thus, UAAs have been
employed as building blocks with the aim of introducing confor-
mational constraints and optimizing ﬁt (i.e., tertiary structure)
and interactions (e.g., hydrogen bonding and electrostatic or
hydrophobic interactions) with the target active site.
Of the several classes of UAAs that are available, examples of
cyclic and bicyclic proline-like amino acids and non-proteinogenic
AAs bearing aromatic or cyclic aliphatic side chains are herein dis-
cussed in more depth. Natural amino acids bearing heavy atoms
(i.e., S, O, and N) suitable for further derivatization provide a large
number of possible UAAs. Serine, threonine, cysteine and tyrosine,
along with acidic and basic residues, as already discussed in the
previous section, could potentially undergo easy transformations
and derivatizations. Although this strategy represents the most
intuitive and facile approach for introducing structural and/or
chemical diversity, only a small number of UAAs of this class were
successfully incorporated into approved drugs. Abarelix23 (Fig. 7,
compound 1, GlaxoSmithKline) is a gonadotropin-releasing
hormone (GnRH) antagonist that contains an N-isopropyl lysine,
Lacosamide24 (Fig. 7, compound 2, NewBridge Pharmaceuticals)
displays an O-methyl-serine residue, Pasireotide (Fig. 7, compound
3) contains an O-benzyl-tyrosine, and the orphan drug Histrelin25
(Fig. 7, compound 4, Ortho-McNeil-Janssen) has a benzyl-bearing
histidine.
Amino acidic scaffolds that exhibit tunable annular side chains
are well known features in peptidomimetic design. In fact, the rel-
evance of proline-like UAAs to drug discovery is primarily attrib-
uted to their typical characteristics, which can inﬂuence the
secondary structure of a molecule. Because they contain no amide
hydrogen, these molecules cannot donate a hydrogen bond and
they possess a certain structural rigidity. Moreover, (i) the modula-
tion of the ‘backbone’ rigidity by increasing the number of atoms in
the ring (see the Sanoﬁ products Bupivacaine26 and Quinupristin,27
Fig. 7, compounds 5 and 6, respectively) and (ii) the ability to
Figure 6. Synthesis of UAAs by side chain modiﬁcation of natural AAs: (a) synthesis of precursors for novel amino acids with a basic side chain via Catellani reaction; (b)
stereoselective synthesis of 2- and 3-indolylglycine derivatives and their oxygen analogues starting from 2-iodoheteroarenes.
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derivatized substrate (i.e., hydroxyproline, Hyp) represent key
strengths of these molecular tools. Several antiviral drugs exhibit
an unnatural derivatized proline; the Hepatitis C virus-Nonstruc-
tural protein 3 (HCV-NS3) protease inhibitors Asunaprevir28
(Fig. 7, compound 7, Bristol-Myers Squibb) and Faldaprevir29
(Fig. 7, compound 8, Boehringer Ingelheim, pre-registered) share
a large portion of their structures and differ primarily with respect
to the substituent at the hydroxyl group of the Hyp. Another sub-
stitution of the Hyp’s OH group is observed in the previously cited
drug Pasireotide30 (Fig. 7, compound 3, Novartis), which was
launched in 2012 for the treatment of Cushing’s disease.
Other very common features are fused bicyclic UAAs, which dis-
play proline-like ﬁve- or six-membered side chains fused with
either aliphatic or aromatic rings. A fused proline side chain is
clearly detectable in Boceprevir31 (Fig. 7, compound 9, Merck),
which is a new HCV NS3 protease inhibitor, in the bradykinin B2
antagonist Icatibant (Fig. 7, compound 10, Sanoﬁ),32 and in
Telaprevir (Fig. 7, compound 11).33 These UAAs provide increased
steric hindrance and enhanced favorable hydrophobic interactions
compared to the corresponding monocyclic analogues.
In addition to proline-like UAAs, several approved drugs have
been synthesized using speciﬁc (ad hoc) non-proteinogenic resi-
dues, primarily with the aim of enhancing binding activity or
improving drug proﬁles. Among these drugs, amino acidic scaffolds
bearing aromatic side chains are quite common. Phenylglycine (in
either the L- or D-form) is one of themostwidely employed aromatic
UAAs. As the inferior homologue of phenylalanine, this amino acid
takes advantage of the main features of phenylalanine with less
degrees of freedom. Phenylglycine is embedded in the antibiotics
Apalcillin (Fig. 7, compound 12, Boehringer Ingelheim), Mezlocillin
(Fig. 7, compound 13, Bayer) and Pivampicillin (Fig. 7, compound
14, LEO Pharma) and in the cyclic hexapeptide Pasireotide (Fig. 7,
compound 3). Besides phenylglycine, the depsipeptide Quinupristin
(Fig. 7, compound 6) displays an N,N-dimethyl-4-aminophenylala-
nine. Higher phenylalanine homologues, such as homophenylala-
nine, are also detectable in approved drugs. As an example, see the
proteasome inhibitor Kyprolis34 (Fig. 7, compound 15, Amgen).
Naphthylalanine is often present in self-assembled compounds
(see below in the text) and is frequently enclosed in peptidic
scaffolds to modulate weak, non-local, protein–ligand interactions,
such as p–p or cation–p. The condensed rings represent efﬁcient
fragments that can ﬁt into deep and ﬂat hydrophobic binding pock-
ets that display narrow breaches. Lanreotide (Fig. 7, compound 16),
which is a somatostatin receptor agonist, and the radioligand[68Ga]-DOTA-NOC35 (Fig. 7, compound 17) both exhibit a cyclic
fragmentwith a sulfur bridge anda D-naphthylalanine in thepeptide
sequence. In contrast, the L-enantiomer residue is oneof thebuilding
blocks of Abarelix23 (Fig. 7, compound 1, GlaxoSmithKline), which is
a GnRH antagonist.
In addition to one naphthylalanine residue, Abarelix contains
the L-3-pyridin-3-ylalanine residue in its peptide sequence. This
residue as well as 3-(2-thienyl)alanine, which is incorporated into
Icatibant (Fig. 7, compound 10, Sanoﬁ),32 are interesting aromatic
building blocks characterized by a heterocyclic side chain.
UAAs with side chains that bear non-aromatic cycles, with and
without heteroatoms, exhibit common six-membered or more
complex architectures. Boceprevir (Fig. 7, compound 9, Merck)31
includes a cyclobutylalanine in its peptide sequence, Telaprevir
(Fig. 7, compound 11)33 exhibits an a-cyclohexylglycine, and
Cobicistat (Fig. 7, compound 18),36 which is an HIV protease inhib-
itor, has 2-amino-4-(4-morpholinyl) butanoic acid as a building
block. The dipeptidyl peptidase IV inhibitor Saxagliptin37 (Fig. 7,
compound 19, Bristol-Myers Squibb) displays the bulky and
hydrophobic (S)-2-amino-2-(3-hydroxy-1-adamantyl)-acetic acid
substructure, in an amount that is equivalent to nearly 50% of
the total molecular weight.
Applications: Engineered amino acid entities are typically asso-
ciated with conventional drug discoveries, but in the last decade,
an increasing number of applications involving UAAs have been
reported in the ﬁeld of life sciences. Indeed the manipulation of
the amino acidic scaffold can be regarded as a potentially powerful
tool in both biochemical investigations and the development of
biomedical devices, whereas the unique properties of peptides
motivated their use in apparently exotic scientiﬁc ﬁelds, not
directly related to the pharmaceutical or healthcare industries
(see Fig. 8). The aim of the current section is to compile a concise
but hopefully complete overview of the non-trivial applications
of UAAs and to highlight potential future developments. The cen-
tral idea is to illustrate all reported applications involving UAAs,
neglecting the most obvious applications related to traditional
drug discovery (see Fig. 8). We focus on two main subjects: (i)
the replacement of natural residues to expand the lexicon related
to proteins, (ii) ‘soft’ and/or ‘wet’ materials that relate to the ability
of peptides to build spontaneously complex supramolecular
structures.
The discovery of the amber codon suppression technique in
recent decades38 revealed a new and intriguing role of UAAs: the
opportunity to introduce in proteins residues bearing different side
chains that were designed a priori. This technique provides a
Figure 7. Examples of currently available registered drugs displaying UAA substructures.
5354 A. Stevenazzi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5349–5356remarkable chance (i) to expand the number of reactions that a
protein can undergo at the post-translational level and (ii) to
locally manipulate the physical and chemical properties of theproteins. Although several conditions should be satisﬁed (i.e., a
large perturbation induced by the engineered side chain should
be avoided), more than 70 new chemical entities have been
Figure 8. Use of UAAs in life sciences: soft matter (self-assembly), bioconjugates (ﬂuorescent probe, spin labeled amino acids, antibody-drug conjugates, ADCs) and
biomedical materials (bone clays).
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the number of adoptable UAAs in proteic lexicon expansion is actu-
ally unknown.39 New synthetic routes in combination with a more
rigorous stoichiometry and localization of the involved reactive
sites suggest an imminent and relevant improvement of bioconju-
gate devices, in which a protein is covalently linked to a drug, a
probe, or a generic chemical entity through a speciﬁc linker that
can release or activate the payload under particular environmental
stimuli. The well-known antibody-drug conjugates40,41 (ADCs) typ-
ically exhibit a drug (i.e., payload) that is connected to deﬁned res-
idues of the antibody through a linker. The drawbacks related to
the post-translational antibody modiﬁcations restricted to protein-
ogenic residues are (i) the limited number of reactions available
and (ii) the poor control of the stoichiometry that is caused by
the presence of multiple reacting amino acids in the proteic chains,
which each have the potential to exhibit different behavior. Axup
and coworkers42 recently reported a new bioconjugate of Trast-
uzumab in which exposed lysines and cysteines on the light chain
(or alanines in the antibody’s sequence) are replaced with a para-
acetylphenylalanine, where the new reactive group permitted the
covalent ligation of Auristatin using an alkoxy-amine precursor
of the cytotoxic compound. It is worth noting that several ADC
platforms based on unnatural residues are currently under active
development, although the potential immunogenicity of the result-
ing engineered proteins must still be assessed.43 The increasing
number of available synthetic routes is apparently improving even
the activity of ADCs, as uncleavable bonds between anticancer
agents and related moieties may result in an enhanced stability
of the antibody towards lysosome degradation.
The ability to introduce exogenous residues into engineered pro-
teins accelerated the discovery of new ﬂuorescent probes,44 whichare precious tools in both imaging and the elucidation of themolec-
ular mechanisms of drugs. A relatively large number of papers
describing amino acidic entities bearing ﬂuorophores (such as
amino acid derivatives of 4-N,N-dimethylaminophthalimide (4-
DMAP) and 6-N,N-dimethylamino-2,3-naphthalimide (6-DMN) on
their side chains is currently available.45 Peptides or proteins bear-
ing paramagnetic UAAs (although due to a posteriori derivatization
of natural residues) can bemonitored using electron spin resonance
spectroscopy: TOAC (4-amino-1-oxyl-2,2,6,6-tetramethyl-
piperidine-4-carboxylic acid) and/or pyrroline nitroxide-containing
amino acids have been successfully inserted into oligopeptides via a
chemoselective ligation of the paramagnetic core structure at the
unique lysine that is available in the test peptide.
One of the most interesting properties of several polymeric
chains is their ability to originate supramolecular architectures.46
Due to the particular intermolecular interactions that occur
between monomers and in the presence of speciﬁc conditions
(ionic strength, temperature and solvent effects), the mesoscale
structures can exhibit several complex morphologies: ﬂat assem-
blies can bend and originate single or multi-layer wall cylinders
or evolve toward microspheres. The resulting intermolecular inter-
action networks show the pivotal role of side chains in the control
of the assembly at the molecular level: modulation of chemical and
physical properties of residues can allow change of shape and size
of the ﬁnal nano/micro-objects. Cyclopeptides with D-amino acids
in their sequence are well known monomers for self-assembled
nanostructures due to their unique ability to stack along a privi-
leged direction in long ﬁbers.47 The inclusion of UAAs bearing
unnatural side chains in the sequence of the monomer can enhance
or induce assembly: naphthylalanine is likely to be the key feature
in the self-assembly of the somatostatin agonist Lanreotide in long
5356 A. Stevenazzi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5349–5356cylinders:48 the resulting macroscopic gel exhibits a very high
degree of viscosity and was adopted as a long acting release
(LAR) formulation for the treatment of acromegaly. An intriguing
application of peptide-based soft matter is the use as tridimen-
sional template for cell cultures. A slab of the self-assembled mate-
rial is spread onto a plastic support with a peculiar 3Dmorphology,
allowing cell growth on the exposed surface, whereas a continuous
layer of cellular entities, which eventually correspond to a tissue,
can grow on the exposed surface. Several hydrogels (i.e., Fmoc
diphenylalanine in water) were investigated as a potential frame-
work for 3D cell culture: although the most relevant examples
are made of natural amino acid polymers, several attempts were
made using D-enantiomers of proteinogenic residues.49 Other
interesting studies related to the adoption of unnatural amino
acids have been conducted in the ﬁeld of tissue engineering con-
cern the development of new collagen-mimetic peptides.50 Besides
the obvious peptides made from naturally occurring amino acids,
oligopeptides that bear one or more unnatural residues, such as
4-(R)-ﬂuoroproline (Flp), were designed in the last decade as a tool
for elucidating the crucial role of the naturally occurring molecule
4-(R)-hydroxyproline (Hyp), which is intrinsically a UAA entity, in
the triple helix stability of collagen. Tailored side chains also allow
new strategies in the search of a balance between mechanical
properties and biocompatibility of several biomaterials: Katti
et al. reported an increased ﬂexibility of montmorillonite-based
bone cements after the introduction of amino acids with aliphatic
side chains into the free volume between two adjacent layers.51
Intercalation is not the only example of inorganic frameworks that
can proﬁtably host natural and unnatural amino acids, allowing
possible future applications in life science: both UAAs and natu-
rally occurring residues may be included52,53 in the synthesis of
metal–organic frameworks (MOFs) as organic ligands of the target
metal ion/atom, an emerging class of materials, with a low density,
a large surface area and an adjustable pore size.54
In summary, the brief overview provided herein clearly
describes the large amount interest that simple molecules, such
as amino acids and their UAA analogues, continue to attract. These
molecules continue to represent important and versatile tools that
can be used by chemists for the preparation of chiral and variously
substituted scaffolds that can be applied in areas that span from
drug discovery to catalysis and from solid phase synthesis to bio-
polymers. Sophisticated techniques, such as amber codon suppres-
sion and the intercalation or encapsulation of UAAs, allow the
integration of new chemistry into biological or inorganic materials,
offering advanced approaches for the chemical manipulation of the
structure and function of those materials. The use of novel UAAs
widens the exploration of the chemical space and opens exciting
new opportunities in basic and applied science research.
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